Search

Pharming Group NV

Slēgts

0.706 -1.53

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

0.697

Max

0.731

Galvenie mērījumi

By Trading Economics

Ienākumi

259K

-959K

Pārdošana

756K

75M

EPS

0.005

Peļņas marža

-1.281

EBITDA

1.9M

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 8. maijs

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

534M

Iepriekšējā atvēršanas cena

2.24

Iepriekšējā slēgšanas cena

0.706

Pharming Group NV Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 4. apr. 22:38 UTC

Karstas akcijas

Stocks to Watch: Eli Lilly, Novo Nordisk, Hims & Hers, Maxeon Solar Technologies

2025. g. 4. apr. 21:53 UTC

Tirgus saruna

Maxeon's Supply Chain Move at Critical Time for Solar Panel Cos -- Market Talk

2025. g. 4. apr. 21:44 UTC

Top Ziņas
Iegādes, apvienošanās, pārņemšana

Trump Grants 75-Day Extension to Reach TikTok Deal -- 3rd Update

2025. g. 4. apr. 21:00 UTC

Top Ziņas

Americans Were Souring on Trump's Economic Plans Even Before Tariff Bloodbath -- WSJ

2025. g. 4. apr. 20:52 UTC

Tirgus saruna

Peloton Likely to Escape Tariffs Unscathed -- Market Talk

2025. g. 4. apr. 20:52 UTC

Top Ziņas

Trump Can Cut Teacher-Training Programs For Now, Supreme Court Says -- WSJ

2025. g. 4. apr. 20:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 4. apr. 20:48 UTC

Top Ziņas

The Score: Nike, Apple, Stellantis and More Stocks That Defined the Week -- WSJ

2025. g. 4. apr. 20:45 UTC

Top Ziņas

Hiring Defied Expectations in March, With 228,000 New Jobs -- 6th Update

2025. g. 4. apr. 20:32 UTC

Top Ziņas

Dow Tumbles 2,000 Points, Bonds Rally After China Retaliates Against Trump Tariffs -- WSJ

2025. g. 4. apr. 20:21 UTC

Top Ziņas

China Hits Back at Trump With Sweeping Tariffs on All U.S. Goods -- Update

2025. g. 4. apr. 20:00 UTC

Top Ziņas

Republicans March Ahead on Trump's Tax Cuts as Tariffs Kick In -- WSJ

2025. g. 4. apr. 19:51 UTC

Tirgus saruna

Dollar Recovers While Recession Fears Grip Wall Street -- Market Talk

2025. g. 4. apr. 19:37 UTC

Top Ziņas

Trump's Team is Getting the Bond Rally It Wanted. But for the Wrong Reasons. -- WSJ

2025. g. 4. apr. 19:32 UTC

Tirgus saruna

Oil Selloff Continues as China Responds to U.S. Tariffs -- Market Talk

2025. g. 4. apr. 19:28 UTC

Top Ziņas

U.S. Stocks Fall Further After China Retaliates Against Trump Tariffs -- Update

2025. g. 4. apr. 19:15 UTC

Tirgus saruna

Costco Gold, Membership Fees Could Help Cushion from Tariff Costs -- Market Talk

2025. g. 4. apr. 19:12 UTC

Top Ziņas

Powell Warns of Higher Prices, Weaker Growth After Tariff Plan -- 3rd Update

2025. g. 4. apr. 19:11 UTC

Tirgus saruna

U.S. Natural Gas Falls as Global Selloff Continues -- Market Talk

2025. g. 4. apr. 19:09 UTC

Tirgus saruna

Mexican Stocks, Peso Tumble as Global Rout Continues -- Market Talk

2025. g. 4. apr. 19:09 UTC

Top Ziņas

Trump Grants 75-Day Extension to Reach TikTok Deal -- Second Update

2025. g. 4. apr. 19:00 UTC

Tirgus saruna

Fed Has Limited Options to Counter Tariffs -- Market Talk

2025. g. 4. apr. 18:53 UTC

Tirgus saruna

Brace for Trump's Tariff Order to Remain in Place for Extended Period -- Market Talk

2025. g. 4. apr. 18:51 UTC

Tirgus saruna

Morgan Stanley Analysts Outline Paths to Recession -- Market Talk

2025. g. 4. apr. 18:44 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2025. g. 4. apr. 18:44 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 4. apr. 18:44 UTC

Tirgus saruna

Tariffs Won't Achieve What Trump Wants, Morgan Stanley Says -- Market Talk

2025. g. 4. apr. 18:43 UTC

Iegādes, apvienošanās, pārņemšana

Trump Extends Deadline for TikTok Ban Another 75 Days. ByteDance Says 'An Agreement Has Not Been Executed.' -- Barrons.com

2025. g. 4. apr. 18:43 UTC

Iegādes, apvienošanās, pārņemšana

Trump Extends TikTok Ban Deadline A Second Time As Deal Chatter Swirls -- IBD

2025. g. 4. apr. 18:39 UTC

Tirgus saruna

Protectionism is Back, And Recession Could Follow, Morgan Stanley Says -- Market Talk

Pharming Group NV Prognoze

Vērtējuma vienprātība

By TipRanks

0 ratings

0

Pirkt

0

Turēt

0

Pārdot

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Pharming Group NV

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.